Publications by authors named "Chitra R Natalie"
Aim: Lebrikizumab is an interleukin (IL)-13 inhibitor that specifically blocks IL-13 signaling. Here, we report the effects of lebrikizumab on asthma serum biomarkers in 2 phase 3 clinical studies.
Methods: LAVOLTA I and LAVOLTA II are replicate, double-blind, placebo-controlled trials with 52-week placebo-controlled treatment periods that evaluated lebrikizumab 37.
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.
J Allergy Clin Immunol Pract
May 2024
Article Synopsis
- The LAVOLTA (L)I, LII, and ACOUSTICS trials tested the asthma treatment lebrikizumab, targeting IL-13, but previously showed mixed results due to patient selection issues.
- The study aimed to analyze the effectiveness of lebrikizumab in patients with high blood eosinophil counts and a history of asthma exacerbations, focusing on a specific subpopulation for more accurate results.
- Results indicated that lebrikizumab significantly reduced asthma exacerbation rates in both adults and adolescents with these criteria, and most side effects were mild or moderate.
Article Synopsis
- Atopic dermatitis (AD) is a chronic skin condition with few treatment options for teens, and lebrikizumab, an antibody targeting IL-13, shows potential benefits in treating it, based on previous studies.
- The Phase 3 ADore study involved 206 adolescents with moderate-to-severe AD, who received lebrikizumab and were monitored for safety and effectiveness over 52 weeks.
- Out of 172 participants who completed the study, many experienced improvements, such as 65% achieving significant reductions in disease severity, while serious side effects were infrequent, indicating the treatment's promise for managing AD in adolescents.
Article Synopsis
- Lebrikizumab is a monoclonal antibody that effectively inhibits the action of interleukin-13, targeting issues related to moderate-to-severe atopic dermatitis in adolescents and adults.
- Safety data was collected from various clinical trials, including placebo-controlled and open-label studies, involving over 1700 patients to assess treatment-emergent adverse events (TEAEs).
- Most reported TEAEs were mild or moderate, with similar frequencies of side effects such as conjunctivitis and injection site reactions in both treatment and placebo groups, showing lebrikizumab has a favorable safety profile.
Article Synopsis
- Lebrikizumab is a new monoclonal antibody targeting IL-13, aimed at treating moderate-to-severe atopic dermatitis in adolescents and adults over 52 weeks in two clinical trials (ADvocate1 and ADvocate2).
- After the initial 16-week treatment, patients were re-randomized to receive either lebrikizumab every 2 weeks, every 4 weeks, or a placebo, with success measured by significant improvements in eczema severity and symptoms.
- Results showed that a high percentage of patients on lebrikizumab (71.2% Q2W, 76.9% Q4W) maintained improvements after 52 weeks, with most side effects reported being mild to
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
Eric L Simpson Melinda Gooderham Andreas Wollenberg Stephan Weidinger April Armstrong Chitra R Natalie
JAMA Dermatol
February 2023
Article Synopsis
- Lebrikizumab (LEB) is a monoclonal antibody that effectively treats moderate-to-severe atopic dermatitis (AD) and was tested in a 16-week trial combined with topical corticosteroids (TCS).
- The ADhere trial included 211 participants, randomized to receive either LEB or a placebo, and assessed outcomes like the improvement in skin condition and quality of life.
- Results showed that significantly more patients on LEB achieved favorable skin health scores compared to those on placebo, indicating better efficacy of the treatment.